{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T21:14:34Z","timestamp":1791580474399,"version":"4.3.4"},"reference-count":23,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100020097","name":"Foundation for Opioid Response Efforts","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100020097","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","japha.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the American Pharmacists Association"],"published-print":{"date-parts":[[2023,7]]},"DOI":"10.1016\/j.japh.2023.04.016","type":"journal-article","created":{"date-parts":[[2023,4,23]],"date-time":"2023-04-23T19:28:20Z","timestamp":1682278100000},"page":"1039-1043","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"title":["The impact of the mainstreaming addiction treatment act and associated legislative action on pharmacy practice"],"prefix":"10.1016","volume":"63","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9795-8837","authenticated-orcid":false,"given":"Tyler J.","family":"Varisco","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4832-8200","authenticated-orcid":false,"given":"Matthew","family":"Wanat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5958-0159","authenticated-orcid":false,"given":"Lucas G.","family":"Hill","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6017-7500","authenticated-orcid":false,"given":"Douglas","family":"Thornton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"10","key":"10.1016\/j.japh.2023.04.016_bib1","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2021.29409","article-title":"Trends in and characteristics of buprenorphine misuse among adults in the US","volume":"4","author":"Han","year":"2021","journal-title":"JAMA Netw Open"},{"issue":"11","key":"10.1016\/j.japh.2023.04.016_bib2","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1176\/appi.ps.201900163","article-title":"Use of drug treatment services among adults with opioid use disorder: rates, patterns, and correlates","volume":"70","author":"Rhee","year":"2019","journal-title":"Psychiatr Serv"},{"issue":"2","key":"10.1016\/j.japh.2023.04.016_bib3","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1093\/heapol\/czh009","article-title":"Overcoming barriers to health service access: influencing the demand side","volume":"19","author":"Ensor","year":"2004","journal-title":"Health Policy Plan"},{"issue":"4","key":"10.1016\/j.japh.2023.04.016_bib4","first-page":"272","article-title":"DEA disconnect leads to buprenorphine bottlenecks","volume":"15","author":"Ostrach","year":"2021","journal-title":"J\u00a0Addict Med"},{"issue":"8","key":"10.1016\/j.japh.2023.04.016_bib8","doi-asserted-by":"crossref","DOI":"10.1001\/jamahealthforum.2022.2839","article-title":"Federal and state pharmacy regulations and dispensing barriers to buprenorphine access at retail pharmacies in the US","volume":"3","author":"Qato","year":"2022","journal-title":"JAMA Health Forum"},{"key":"10.1016\/j.japh.2023.04.016_bib11","doi-asserted-by":"crossref","DOI":"10.1016\/j.drugalcdep.2022.109518","article-title":"Availability of buprenorphine\/naloxone films and naloxone nasal spray in community pharmacies in 11 U.S. states","volume":"237","author":"Hill","year":"2022","journal-title":"Drug Alcohol Depend"},{"issue":"2s","key":"10.1016\/j.japh.2023.04.016_bib12","doi-asserted-by":"crossref","first-page":"S12","DOI":"10.1016\/j.japh.2016.12.070","article-title":"Pharmacists\u2019 readiness to provide naloxone in community pharmacies in West Virginia","volume":"57","author":"Thornton","year":"2017","journal-title":"J\u00a0Am Pharm Assoc (2003)"},{"key":"10.1016\/j.japh.2023.04.016_bib13","article-title":"Rural community pharmacist willingness to dispense Suboxone\u00ae-a secret shopper investigation in South-Central Appalachia","volume":"4","author":"Trull","year":"2021","journal-title":"Explor Res Clin Soc Pharm"},{"key":"10.1016\/j.japh.2023.04.016_bib14","doi-asserted-by":"crossref","DOI":"10.1016\/j.drugpo.2020.102701","article-title":"Buprenorphine dispensing in an epicenter of the U.S. opioid epidemic: a case study of the rural risk environment in Appalachian Kentucky","volume":"85","author":"Cooper","year":"2020","journal-title":"Int J Drug Policy"},{"issue":"1","key":"10.1016\/j.japh.2023.04.016_bib15","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1016\/j.japh.2022.08.017","article-title":"Perceptions, policies, and practices related to dispensing buprenorphine for opioid use disorder: a national survey of community-based pharmacists","volume":"63","author":"Hill","year":"2023","journal-title":"J\u00a0Am Pharm Assostc (2003)"},{"key":"10.1016\/j.japh.2023.04.016_bib16","article-title":"Factors in rural community buprenorphine dispensing","volume":"9","author":"Major","year":"2023","journal-title":"Explor Res Clin Soc Pharm"},{"key":"10.1016\/j.japh.2023.04.016_bib18","article-title":"Patient-reported problems filling buprenorphine prescriptions and motivations for illicit use","volume":"5","author":"Winstanley","year":"2022","journal-title":"Drug Alcohol Depend Rep"},{"key":"10.1016\/j.japh.2023.04.016_bib19","doi-asserted-by":"crossref","DOI":"10.1016\/j.drugpo.2022.103703","article-title":"\u2018Red Flags\u2019 and \u2018Red Tape\u2019: telehealth and pharmacy-level barriers to buprenorphine in the United States","volume":"105","author":"Textor","year":"2022","journal-title":"Int J Drug Policy"},{"issue":"5","key":"10.1016\/j.japh.2023.04.016_bib20","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1016\/j.japh.2021.04.014","article-title":"Switching Pharmacies leads to gaps in medication possession in individuals treated with buprenorphine","volume":"61","author":"Varisco","year":"2021","journal-title":"J\u00a0Am Pharm Assoc (2003)"},{"key":"10.1016\/j.japh.2023.04.016_bib21","article-title":"A\u00a0content review of buprenorphine training programs for pharmacists","volume":"6","author":"Davis","year":"2022","journal-title":"Explor Res Clin Soc Pharm"},{"issue":"6","key":"10.1016\/j.japh.2023.04.016_bib22","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1016\/j.sapharm.2015.12.008","article-title":"Prescription drug abuse communication: a qualitative analysis of prescriber and pharmacist perceptions and behaviors","volume":"12","author":"Hagemeier","year":"2016","journal-title":"Res. Social Adm. Pharm"},{"issue":"3","key":"10.1016\/j.japh.2023.04.016_bib23","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1080\/10826084.2019.1670210","article-title":"Communication experiences of DATA-waivered physicians with community pharmacists: a qualitative study","volume":"53","author":"Ventricelli","year":"2020","journal-title":"Subst Use Misuse"},{"issue":"2","key":"10.1016\/j.japh.2023.04.016_bib24","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1056\/NEJMc2208055","article-title":"Physician-delegated unobserved induction with buprenorphine in pharmacies","volume":"388","author":"Green","year":"2023","journal-title":"N\u00a0Engl J Med"},{"issue":"2","key":"10.1016\/j.japh.2023.04.016_bib26","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1331\/JAPhA.2015.14177","article-title":"Physician-pharmacist collaborative care model for buprenorphine-maintained opioid-dependent patients","volume":"55","author":"DiPaula","year":"2015","journal-title":"J\u00a0Am Pharm Assoc"},{"issue":"5","key":"10.1016\/j.japh.2023.04.016_bib27","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.1097\/ALN.0000000000000170","article-title":"Buprenorphine-naloxone therapy in pain management","volume":"120","author":"Chen","year":"2014","journal-title":"Anesthesiology"},{"issue":"7","key":"10.1016\/j.japh.2023.04.016_bib28","doi-asserted-by":"crossref","first-page":"1805","DOI":"10.1111\/add.15353","article-title":"Buprenorphine physician-pharmacist collaboration in the management of patients with opioid use disorder: results from a multisite study of the National Drug Abuse Treatment Clinical Trials Network","volume":"116","author":"Wu","year":"2021","journal-title":"Addiction"},{"issue":"10","key":"10.1016\/j.japh.2023.04.016_bib29","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1093\/ajhp\/zxaa060","article-title":"A\u00a0physician-pharmacist collaborative care model to prevent opioid misuse","volume":"77","author":"Lagisetty","year":"2020","journal-title":"Am J Health Syst Pharm"},{"issue":"8","key":"10.1016\/j.japh.2023.04.016_bib30","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1016\/j.sapharm.2018.10.027","article-title":"Using the theory of planned behavior to investigate community pharmacists' beliefs regarding engaging patients about prescription drug misuse","volume":"15","author":"Fleming","year":"2019","journal-title":"Res Social Adm Pharm"}],"container-title":["Journal of the American Pharmacists Association"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1544319123000973?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1544319123000973?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T05:53:29Z","timestamp":1761544409000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1544319123000973"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7]]},"references-count":23,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2023,7]]}},"alternative-id":["S1544319123000973"],"URL":"https:\/\/doi.org\/10.1016\/j.japh.2023.04.016","relation":{},"ISSN":["1544-3191"],"issn-type":[{"value":"1544-3191","type":"print"}],"subject":[],"published":{"date-parts":[[2023,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The impact of the mainstreaming addiction treatment act and associated legislative action on pharmacy practice","name":"articletitle","label":"Article Title"},{"value":"Journal of the American Pharmacists Association","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.japh.2023.04.016","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 American Pharmacists Association\u00ae. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}